COVID-19 Update – SERO is open. We continue to consult, evaluate and treat patients and their families at our existing locations.

Gordon Guo, MD

Gordon Guo, MD

workRadiation Oncologist
location_onAtrium Health – Lancaster Radiation Therapy Center

About Dr. Guo


North Carolina

Board Certification

American Society of Radiation Oncology (ASTRO)

American Brachytherapy Society (ABS)

ABR Online Longitudinal Assessment (OLA)


Mount Sinai Beth Israel

2015 — 2016

New York, NY

Brachytherapy Fellowship

University of Manitoba

2010 — 2015

Winnipeg, Manitoba, Canada

Radiation Oncology Residency

MD Anderson Cancer Center


Houston, TX

Resident Elective

University of Toronto

- 2007

Toronto, Ontario, Canada

Doctor of Medicine

University of Waterloo

- 2003

Waterloo, Ontario, Canada

Doctor of Medicine


Assistant Professor, GU/GYN Service Chief, Brachytherapy Service Chief, Indiana University Simon Cancer Center


Indianapolis, IN

Assistant Professor, Department of Radiation Oncology, University Hospitals Seidman Cancer Center


Cleveland OH


  • Gordon Guo, Zainab Almomen, Brady Cripe, Drew Hedges, William Rios Izquierdo The Planned vs Actual Dosimetric Effect of Bladder Filling on Patients receiving salvage pelvic radiotherapy after prostatectomy Accepted for publication. Radiation Therapist 2021
  • Gordon Guo, Keith Sutherland, Candace Myers Pascal Lambert, Harvey Quon. Prospective swallowing outcomes after IMRT for oropharyngeal cancer: dosimetric correlations in a population-based cohort. Oral Ocology. 2016 Oct; 61:135-41
  • Henan Zhao, Xiaotang Yu, Yanfang Ding, Jinyao Zhao, Guang Wang, Xian Wu, Jiyong Jiang, Chun Peng, Gordon Zhuo Guo, Shiying Cui. MiR-770 5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 Oncotarget. 2016 Aug 16; 7(33): 53254–53268
  • Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo G, Jiang J, Cui S Expression of mir-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncology reports 2015;33:591-598.
  • Zhang X, Guo G, Wang G, et al. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of mir-510 in ovarian carcinoma. Molecular medicine reports 2015;12:8021-8031.
  • Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, Jia T, Han D, Guo G, Wang B, Jiang J, Cui S. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biology 2013;34:3501-3508.
  • Zhao JY, Liu CQ, Zhao HN, Ding YF, Bi T, Wang B, Lin XC, Guo G, Cui SY. Synchronous detection of miRNAs, their targets and downstream proteins n t ransferred FFPE sections: Applications in clinical and basic research. Methods. 2012;58:156-163.
  • Guo G, Morrison DJ, Licht JD and Quaggin SE. WT1 activates a glomerular-specific enhancer identified from the Human Nephrin Gene Journal of American Society of Nephrology: JASN 2004;15:2851-2856.


  • McClelland S 3rd, Le Y, Ng SK, Guo GZ: Can HDR Brachytherapy Achieve superior Proximal Seminal Vesicle Coverage to LDR brachytherapy? A DOsimetric Comparison of two Brachytherapy Boost Modalities. Abstract 20000697, Radiological Society of North America, 106th Annual Meeting, 2020.
  • Yi Le, Zheng Gu, Matthew Napiwocki, Gordon Watson, Gordon Guo. A plan quality assurance QA) method for HDR breast brachytherapy with multi-lumen balloon applicator and HDR interstitial prostate brachytherapy American Brachytherapy Society Meeting, Miami, FL, 2019
  • Hinton J, Schilder J, Guo, G. High-dose-rate Brachytherapy following concurrent chemoradiotherapy for locally advanced cervical cancer: Early outcomes after adoption of MRI-Guided 3-D volumetric planning American Brachytherapy Society Annual Meeting, San Francisco, CA. 2018
  • Gordon Guo, Lawrence Tena, Tracy Ng. High-dose-rate Brachytherapy boost in addition to IMRT for nasopharyngeal carcinoma ASTRO Annual Scientific Meeting, Boston, MA. 2016
  • Gordon Guo, Pascal Lambert, Naseer Ahmed, Garry Schroeder, Derek Fewer, Shaun Loewen. Aggressive local therapy may improve survival in NSCLC patients with limited brain metastases ASTRO Annual Scientific Meeting, San Francisco, CA. 2014
  • Gordon Guo, Candace Myers, Keith Sutherland, Pascal Lambert, Jim Butler, Harvey Quon. Prospective swallowing outcomes after IMRT for oropharyngeal cancer: dosimetric correlations in a populationbased cohort. ASTRO Annual Scientific Meeting, International Journal of Radiation Oncology * Biology * Physics Vol. 84, Issue 3, Supplement, Page S480. Boston, MA. 2012
  • Goldstein, J., Guo, G., Li,C., S.E. Quaggin. A simple and reproducible genetic model to study glomerulosclerosis in the mouse. American Society of Nephrology 39th Annual Renal Week Meeting. San Diego, CA. 2006
  • Cui, S., Li, J., Guo, G., S.E. Quaggin. Innocent bystander theory for progression to glomerulosclerosis in a transgenic mouse model, American Society of Nephrology, St. Louis, MO. 2004
  • Gordon Guo, Debra J. Morrison, Jonathan D. Licht and Susan E. Quaggin. The Wilms Tumor Suppressor Gene binds to a podocyte-specific enhancer from the Human Nephrin Gene. Annual Conference of American Society of nephrology, San Diego, CA. 2003
  • Gordon Guo, Chenglin Li, Vera Eremina, and Susan E. Quaggin. Podocytopenia leads to glomerulosclerosis in transgenic mice. Annual Conference of American Society of nephrology, San Diego, CA. 2003


Tirkes, Temel (Ed.) Prostate MRI Essentials – A Practical Guide for Radiologists Hardcover ISBN 978-3-030-45934-5 eBook ISBN 978-3-030-45935-2 Springer International Publishing 2020 Chapter 11: Prostate MRI from Radiation Oncology Perspective


  • NRG GU Committee
  • NRG Cervix Cancer Committee
  • For Radiation Oncology Question Writing Committee
  • CWRU Radiation Research Safety Committee (RRSC)
  • Faculty Recruitment Committee
  • Medical Residency Interview Committee